Detecting breast cancer : 2D vs 3D imaging by Vassallo, Pierre
bacKgrounD oF the breast cancer awareness month
The month of October has become synonymous with an 
increased awareness of breast cancer. The amount of information 
presented on the media about breast cancer during the month 
of October is frequently overwhelming and often confusing. 
We should not be more aware of breast cancer during October, 
simply because the incidence of breast cancer is the same all year 
around.  However, October serves as a yearly wake-up call to the 
importance of being proactive in the detection and treatment of 
breast cancer. It has also become a calendar event for organising 
fund-raising activities for breast cancer treatment and research. 
The concept of having a Breast Cancer Awareness Month 
was born in 1985 through cooperation between the American 
Cancer Society and Astra Zeneca, a pharmaceutical company 
that was developing breast cancer medicines. Initially, the aim 
was to promote screening with mammography for the early 
detection of breast cancer and to institute treatment early. In 
1993, the Breast Cancer Research Foundation was created in the 
US to source funds for research in breast cancer; the foundation 
and similar societies throughout the world use the month 
of October to promote awareness through education and to 
organise events to raise funds for breast cancer research. 
The month of October sees an abundance of educational 
and promotional information appearing in all the media 
from governmental and private organisations that is aimed 
at enhancing the public awareness of the importance 
of detecting breast cancer early and how this is done. 
Organisations use this month to promote the use of well-
established technologies for breast cancer detection. 
Unfortunately, this month is also used by some companies to 
showcase newly acquired “innovative” technologies that have 
no scientifically proven clinical advantage. 
The article below outlines the well-established and 
scientifically proven technologies, as well as the newer ones, and 
guides the reader on which test should be performed based on 
patient age and clinical background. 
why is breast imaging imPortant?
The answer is short and simple: it reduces the mortality of 
breast cancer. 
Breast cancer is one of the leading causes of death in women 
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Figure 1. CR Mammogram (a) versus FFD Mammogram (b). 
Note the superior image clarity in (b).
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screening reduced the mortality from breast cancer by 45%.2 
This statistic was derived at a time when only mammography 
was used and the quality of mammography was far inferior 
to the image quality obtained by mammography today. With 
modern mammographic methods, we should improve on 
the above quoted findings. However, with the development 
of multiple new techniques for breast cancer screening, it is 
becoming increasingly important to select the right technique 
based on the patients’ needs. Having multiple technologies at 
hand is often leading to a degree of confusion that may delay 
diagnosis and treatment.
technologies aVailable For breast cancer Detection
mammograPhy
Mammography is overall still the best tool for breast cancer 
screening, however, it is important to know its limitations 
and when to use ancillary imaging techniques to improve 
diagnostic accuracy. 
Mammographic images have seen big improvements 
in quality resulting from technological development 
over the past two decades. The shift from conventional 
film/screen mammography to digital mammography 
resulted in improvement in image quality and reduction 
of radiation exposure. Digital mammography underwent 
further development from Computed Radiography (CR) 
Mammography to Full Field Digital (FFD) Mammography. 
The introduction of FFD mammograms brought about 
the biggest overall improvement in image quality and in 
diagnostic accuracy. 
When referring to mammography today, we should no 
longer consider performing film/screen mammograms or 
CR mammograms as they are diagnostically inferior to FFD 
mammograms (Fig 1). Only FFD mammograms should be 
performed today.
FFD mammograms are low dose X-ray images of the 
breast that depict internal structure based on tissue density. 
There are two main types of normal tissue in the breast, 
breast glands and ducts which are dense, and fat which is 
low density. The overall density of the breast reflects the 
proportion of glands/ducts to fat. Very glandular breasts are 
dense, while very fatty breasts are non-dense. 
Cancers are dense on mammograms and are hence better 
seen on a fatty background than on a glandular background. In 
the case of very dense breasts, which may account for 20-40% 
of the screening population, cancers may be difficult to detect 
and may require additional imaging methods to ensure an 
accurate diagnosis. 
The most cost-effective and efficient ancillary imaging 
method for dense breasts, when combined FFD mammograms, 
is breast ultrasound (Fig 2). This is quick and poses no 
additional radiation exposure to the patient. It can also be used 
to guide immediate biopsy to expedite further management. 
Recent years have seen the development of breast 
Tomosynthesis (“3D mammograms”), which is a further 
development of digital mammographic technology; this 
system obtains image slices through the breast to reduce 
overlap of glandular tissue (Fig 3). Tomosynthesis is 
beneficial when combined with FFD mammography 
for dense breasts, but since it is done following FFD 
mammography, this results in doubling of the radiation 
exposure dose to the patient. Besides, proceeding to a breast 
ultrasound instead of Tomosynthesis often delivers the same 
results, while reducing the radiation exposure and cost. 
Ultrasound also has the added advantage of allowing efficient 
and immediate biopsy that expedites management. 
To date, the use of Tomosynthesis alone has not be clinically 
accepted as a primary screening method for breast cancer. 
breast ultrasounD
Breast ultrasound is a valuable adjunct to FFD mammography 
when screening for breast cancer.3 Combining the two tests 
increases diagnostic accuracy particularly in dense breasts. 
Breast ultrasound alone may be used for screening younger 
women (<40 years of age), particularly for those who have very 
dense breasts and for those who have breast implants. 
Beast ultrasound is a test that requires direct hands-on 
intervention by a breast radiologist. The radiologist should be 
experienced in performing breast ultrasound, should be aware of any 
relevant clinical symptoms or findings before performing the scan, 
Figure 3. FFD (2D) Mammogram (a) versus Tomosynthesis (b): Tomosynthesis 
may be used as an ancillary test to evaluate abnormalities detected on FFD 
mammograms; note cancer (in box) seen on both images.
Figure 2. FFD Mammogram showing a moderately dense breast that obscures a 
clinically noted medial breast nodule (a) and ancillary imaging with ultrasound 
(b) confirming the presence of a small cancer (arrows).
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should ensure full coverage of all breast tissue and axillary regions 
and should maintain open communication with the patient during 
the scan as she may provide information that could be relevant to the 
procedure. The radiologist should be aware of all mammographic 
findings and should have correlated those findings with previous 
exams prior to performing an adjunct breast ultrasound scan. 
Any attempts at saving radiologist time by employing 
ultrasound technologists or automated breast ultrasound scanners 
(ABUS or 3D scanners) results in loss of this open clinical 
encounter, with the ensuing risk of loosing valuable information 
from the diagnostic process. The radiologist should have direct 
access to the patient, must review previous mammograms and 
must perform the ultrasound scan to ensure that all sources of 
data are integrated to deliver the most accurate diagnosis. 
ABUS scanners have been in the market for the past 10 
years; they have not yet been shown to be reliable enough to 
replace normal breast ultrasound for breast cancer screening. 
There are numerous issues that limit the value of ABUS as a 
diagnostic test: (1) There are risks that the scan will not cover 
the whole breast, particularly the axillary regions; (2) in saving 
radiologist’s time, it reduces communication between the patient 
and the radiologist, which may result in clinical findings such 
as skin puckering, nipple discharge or a nodule being missed; 
(3) artefacts that occur during a normal ultrasound scan can 
be minimised by an experienced radiologist through changes 
in scanning angle and scanner settings; this is not possible with 
ABUS. If a scan is performed by technologist or a machine 
(in case of ABUS), mammographic and clinical data are not 
integrated to improve the accuracy of the ultrasound scan. 
breast mri
Breast MRI is the most sensitive test for detecting breast 
abnormalities. Certain types of breast cancer, such as early ductal 
carcinoma-in-situ and lobular breast cancer can only be reliably 
detected by MRI. Breast MRI, however, requires an expensive 
scanner, has prolonged examination times in an uncomfortable 
position and requires the use of an injection of contrast material. 
Breast MRI also detects many benign nodules as well as malignant 
ones, which may occasionally result in unnecessary further 
investigation. Still, breast MRI remains the best test to use for 
dense breasts (Fig 4). Breast MRI is still considered to be too 
costly and time-consuming to be used as a routine breast cancer 
screening tool; it is an excellent method for diagnostic workup of 
equivocal findings and for imaging certain types of breast cancer. 
selecting Patients baseD on age
When deciding on the best test for breast cancer screening one 
starts by checking the patient’s age. 
For patients aged 40 years or older, breast cancer screening 
should start with a FFD mammogram. This should be reviewed 
immediately by a breast radiologist, who then proceeds to a direct 
hands-on breast ultrasound if any mammographically equivocal 
or suspicious findings are detected. Interaction between the 
radiologist and the patient is important at this stage as it may 
contribute significant information to the diagnostic process and 
will help reduce the patient’s stress. Proceeding to Tomosynthesis 
before performing an ultrasound may lead to unnecessary radiation 
exposure. Proceeding to a breast MRI or an ultrasound-guided 
biopsy may also be more efficient than employing Tomosynthesis. 
For patients under the age of 40 years, a breast ultrasound should 
be the first examination with direct, hands-on intervention by a 
breast radiologist to ensure that both clinical and ultrasound findings 
are integrated into the final report and treatment recommendations. 
Further investigations, if doubts arise on the ultrasound, may 
include ultrasound-guided biopsy or breast MRI. Mammograms are 
occasionally performed in this age group, but they often contribute 
less information since many of these patients have dense breast. 
conclusion
In summary, FFD mammograms (2D mammograms) are 
fundamental to all breast cancer screening programs, particularly 
since these programs are recommended for women aged 40 years 
and older. They are the best tool we have for detecting breast cancer. 
Direct hands-on breast ultrasound (2D ultrasound) performed by 
an experienced breast specialist contributes important data when 
combined with FFD mammograms and expedites management 
while avoiding additional radiation exposure. 
Tomosynthesis (3D mammograms) should only be used as 
an ancillary test if findings on 2D mammograms and 2D breast 
ultrasound are still unclear. Automated Breast Ultrasound 
(ABUS or 3D ultrasound) does not replace direct hands-on 2D 
breast ultrasound as it will lead to loss of valuable diagnostic 
information that may delay treatment. 
Figure 4. Breast Ultrasound (A), FFD Mammogram (B) and Breast MRI (C and 
D): The images show a less common type of breast cancer, an invasive lobular 
cancer; this type of cancer is poorly seen on FFD mammograms (B) but is 
detected by breast ultrasound (A). However, its full extent can only be seen on 
Breast MRI (C and D); it involves the whole right breast (arrows). Breast MRI is 
the only test that accurately assesses the extent of lobular breast cancer. 
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